arrow
G

Giacomo Cartenì

sapienza university rome
H指数:41
被引数:8,419

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

在意大利扩大访问计划中接受一线nivolumab和ipilimumab的转移性肾细胞癌患者中验证Meet-URO评分

2022-12-0121
OAAI
Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)
2021-09-011
OA
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
2021-01-1813
OAAI
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
2019-08-2915
OAAI
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
2018-07-2366
OAAI
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

舒尼替尼辅助治疗肾切除术后高危肾细胞癌: 亚组分析和更新的总生存结果

2018-01-01174
OAAI
Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory molecular analysis of tumor biomarkers
2017-07-012
PRE